StreetAlpha.app
Home › Stocks › GANX

Gain Therapeutics, Inc. (GANX)

$1.18
▲ +25.51%
LAST CLOSE · NOV 17

Gain Therapeutics develops small molecule drugs for neurological and rare genetic diseases, based in Bethesda, Maryland. It last closed at $1.18 on Nov 17, up 25.51% on the day.

AI Auto Pilots
Is GANX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$18.0M
EPS (diluted)
−$0.42
Valuation
Market cap
$52.5M
44.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$11.7M
At Sep 30
Debt
$309K
At Sep 30
Shareholder equity
$10.2M
Shares outstanding
44.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$13.9M−$13.9MFY2021FY2022: −$17.6M−$17.6MFY2022FY2023: −$22.3M−$22.3MFY2023FY2024: −$20.4M−$20.4MFY2024FY2025: −$20.2M−$20.2MFY2025

From GANX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated GANX in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 578.0% upside

Based on 1 analyst who set a price target on GANX in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.18.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $1.18
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 31Buy$8
BTIGReiterated
Aug 12Buy$5
HC Wainwright & Co.Reiterated
Jul 1Buy$8
BTIGMaintained
Jun 30Buy$5
DateFirmActionRatingPrice target
Aug 31HC Wainwright & Co.ReiteratedBuy$8
Aug 12BTIGReiteratedBuy$5
Jul 1HC Wainwright & Co.ReiteratedBuy$8
Jun 30BTIGMaintainedBuy$5
Loading…

Technical Analysis

GANX · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 53% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the Pivot at $1.15, and the nearest resistance the swing high (Nov 4) at $1.20.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 10.6%/day
Key levels
$4.3452 week high+267.8%
$1.81200 day average+53.4%
$1.64100 day average+39.0%
$1.4450 day average+22.0%
$1.33Pivot R1+12.7%
$1.20Swing high (Nov 4)+1.7%
$1.18Last close
$1.15Pivot−2.5%
$1.14Swing low (Oct 26)−3.4%
$1.1220 day average−5.1%
$1.00Pivot S1−15.3%
$0.9452 week low−20.3%
Indicators
RSI (14)48.26Middle of its rangeNeutral
MACD-0.11Above its signal lineBullish
Stochastic32.9Middle of its rangeNeutral
ADX (14)33.5Trending up
Williams %R-33.3Oversold below −80, overbought above −20Neutral
CCI (20)19.0Oversold below −100, overbought above 100Neutral
Rate of change+2.6%Change over 10 sessionsBullish
ATR (14)$0.12Typical daily range, 10.6% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for GANX

What happened before

See how GANX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow GANX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GANX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in GANX in the last 90 days.

Loading…

See today’s whale options flow across the market →

GANX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●19 buying vs 21 selling
  • ▼Held by funds -1.8 pts
  • ●Funds holding +0
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding50500.0%
In funds' top 1000–
Held by funds19.0%20.7%−1.8 pts
New / increased9 / 1012 / 15−29.6%
Reduced / sold out11 / 109 / 4+61.5%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GANX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GANX is in one of them and how their past GANX trades turned out.

GANX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GANX in an article yet. Here's the latest on the wider market.

About Gain Therapeutics

Gain Therapeutics is a biotechnology company in Bethesda, Maryland, that develops small molecule drugs for diseases caused by misfolded proteins. Its lead candidate, GT-02287, is being tested for Parkinson's disease. The company is also working on treatments for lysosomal storage disorders, metabolic disorders and oncology. It uses its Magellan computational platform to find sites on disease-linked proteins where drugs can bind and to design molecules that fit those sites.

Headquarters
Bethesda, MD